Biogen salue la décision du Québec de rembourser SPINRAZAMC (nusinersen) pour une vaste population de patients atteints d’amyotrophie spinale (AS)
December 20, 2018 12:19 ET
|
Biogen Canada
MISSISSAUGA, Ontario, 20 déc. 2018 (GLOBE NEWSWIRE) -- Cette décision découle de la recommandation positive de l’Institut national d’excellence en santé et services sociaux (INESSS) qui...
Biogen Applauds Quebec Decision to Cover SPINRAZA™ (nusinersen) for a broad population of SMA Patients
December 20, 2018 12:19 ET
|
Biogen Canada
The decision follows positive recommendation from the Institut national d'excellence en santé et services sociaux (INESSS) recognising the urgency and need for a treatment for patients with SMA and...
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
October 06, 2018 07:30 ET
|
Biogen Inc.
NURTURE study participants were alive and did not require permanent ventilation, in contrast to natural history of spinal muscular atrophy (SMA)Study participants achieved motor milestones with 100...
Spotlight Innovation Spinal Muscular Atrophy Research Collaborator Professor Kevin Hodgetts Receives $300,000 Grant from Cure SMA
July 24, 2018 08:55 ET
|
Spotlight Innovation Inc.
URBANDALE, IA, July 24, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company...
Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015
May 31, 2018 07:00 ET
|
Scholar Rock
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of...
Families of SMA and Nationwide Children's Announce Multi-Million Dollar Award From NINDS to Advance CNS Gene Therapy for Spinal Muscular Atrophy
March 13, 2013 13:12 ET
|
Families of SMA
ELK GROVE VILLAGE, Ill., March 13, 2013 (GLOBE NEWSWIRE) -- Nationwide Children's Hospital (Columbus, OH) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announce the award of a...
Pfizer Licenses Families of Spinal Muscular Atrophy Quinazoline Drug Program From Repligen
January 03, 2013 09:31 ET
|
Families of SMA
ELK GROVE VILLAGE, Ill., Jan. 3, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance...
Families of Spinal Muscular Atrophy Committed $2.5 Million to Funding SMA Research in 2012
December 31, 2012 10:06 ET
|
Families of SMA
ELK GROVE VILLAGE, Ill., Dec. 31, 2012 (GLOBE NEWSWIRE) -- Families of SMA is dedicated to creating a treatment and cure for Spinal Muscular Atrophy by funding and advancing a comprehensive research...
Families of Spinal Muscular Atrophy Awards $710,000 for Basic Research to Identify New and More Effective Approaches for SMA Therapies
December 28, 2012 10:07 ET
|
Families of SMA
ELK GROVE VILLAGE, Ill., Dec. 28, 2012 (GLOBE NEWSWIRE) -- Families of SMA is dedicated to creating a treatment and cure for Spinal Muscular Atrophy by funding and advancing a comprehensive research...
Repligen Initiates Phase 1b Trial of RG3039 for Spinal Muscular Atrophy Licensed From Families of SMA
September 26, 2012 16:17 ET
|
Families of SMA
ELK GROVE VILLAGE, Ill., Sept. 26, 2012 (GLOBE NEWSWIRE) -- Repligen Corporation has initiated a Phase 1b clinical study of RG3039, a novel small molecule drug candidate for the potential treatment of...